COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,221 Articles (22,733 medRxiv, 8,488 bioRxiv)

Most recent first Previous |  Page 1120: Articles 11191-11200  | Next

HLA-A*03:01 is associated with increased risk of fever, chills, and more severe reaction to Pfizer-BioNTech COVID-19 vaccination
Bolze, A., Neveux, I., Schiabor Barrett, K. M., White, S., Isaksson, M., Dabe, S., Lee, W., Grzymski, J. J., Washington, N. L., Cirulli, E. T.
10.1101/2021.11.16.21266408 — Posted: 2021-11-20
Encounters after Appointments Cancelled Due to COVID-19 in the Veterans Affairs Health Care System
Tran, L. D., Rose, L., Urech, T., Vashi, A.
10.1101/2021.11.17.21266381 — Posted: 2021-11-20
Durability of anti-Spike antibodies in the infant after maternal COVID-19 vaccination
Shook, L., Atyeo, C. G., Yonker, L. M., Fasano, A., Gray, K. J., Alter, G., Edlow, A. G.
10.1101/2021.11.17.21266415 — Posted: 2021-11-20
Metformin Suppresses SARS-CoV-2 in Cell Culture
Tandel, D., Parthasarathy, H., Harshan, K. H.
10.1101/2021.11.18.469078 — Posted: 2021-11-19
Effects of trust, risk perception, and health behavior on COVID-19 disease burden: Evidence from a multi-state US survey
Ridenhour, B. J., Sarathchandra, D., Seamon, E., Brown, H., Leung, F.-Y., Johnson-Leon, M., Megheib, M., Miller, C. R., Johnson-Leung, J.
10.1101/2021.11.17.21266481 — Posted: 2021-11-19
The unmitigated profile of COVID-19 infectiousness
Sender, R., Bar-On, Y. M., Park, S. W., Noor, E., Dushoffd, J., Milo, R.
10.1101/2021.11.17.21266051 — Posted: 2021-11-19
Anti-SARS-CoV-2 antibodies seroprevalence among patients submitted to treatment for tuberculosis in Rio de Janeiro, Brazil: a cross-sectional study.
Gomes, K. M., Leite, S. P., Moutinho, M. H. V., Souza, T. A. d., Batista, R. d. C., Oliveira, L. C. M. d., Redner, P., Ramos, J. P., Rocha, F. M. G. d., Oliveira, G. P. d., Teva, A., Motta, F. d. C., Siqueira, M. A. M. T. d., Duarte, R. S., Bastos, F. I. P. M., Viana, P. V. d. S.
10.1101/2021.11.17.21266274 — Posted: 2021-11-19
Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds.
Meyer, M., Constancias, F., Worth, C., Meyer, A., Muller, M., Boussuge, A., Kaltenbach, G., Schmitt, E., Chayer, S., Velay, A., Vogel, T., Fafi-Kremer, S., Karcher, P.
10.1101/2021.11.19.21266252 — Posted: 2021-11-19
Low neutralizing antibody titers against the Mu variant of SARS-CoV-2 in BNT162b2 vaccinated individuals
Alvarez-Diaz, D. A., Munoz, A. L., Tavera-Rodriguez, P., Herrera-Sepulveda, M. T., Ruiz-Moreno, H. A., Laiton-Donato, K., Franco-Munoz, C., Pelaez-Carvajal, D., Cuellar, D., Munoz-Ramirez, A. M., Galindo, M., Arias-Ramirez, E. J., Reyes, M. M.
10.1101/2021.11.19.21266552 — Posted: 2021-11-19
Monitoring of SARS-CoV-2 Antibodies Using Dried Blood Spot for At-Home Collection
Miesse, P. K., Collier, B. B., Grant, R. P.
10.1101/2021.11.19.21266532 — Posted: 2021-11-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).